Evaluation of factors influencing antibody reduction for development of antibody drug conjugates

Meghdad, Abdollahpour Alitappeh; Majid, Lotfinia; Sepand, Razavi Vakhshourpour; Saeed, Jahandideh; Hamid, Najminejad; Koushan Sineh, Sepehr; Reza, Moazami; Elnaz, Shams; Mahdi, Habibi Anbouhi; Mohsen, Abolhassani

Meghdad, Abdollahpour Alitappeh; Majid, Lotfinia; Sepand, Razavi Vakhshourpour; Saeed, Jahandideh; Hamid, Najminejad; Koushan Sineh, Sepehr; Reza, Moazami; Elnaz, Shams; Mahdi, Habibi Anbouhi; Mohsen, Abolhassani.

IBJ-Iranian Biomedical Journal. 2017; 21 (4): 270-274

Dans Anglais | IMEMR | ID: emr-189236

ABSTRACT

ABSTRACT

Background:

Reduction/alkylation is one of the leading strategies for the development of antibody drug conjugates [ADCs]. Precise control of the reduction process would not only yield a defined number of free thiols per antibody but also result in development of more homogenous conjugates

Sujets)

Recherche sur Google

Imprimer

XML

Indice: Méditerranée orientale Sujet Principal: Oxydoréduction / Thiols / Température / Préparations pharmaceutiques / Dithiothréitol / Électrophorèse sur gel de polyacrylamide / Alkylation / Trastuzumab langue: Anglais Texte intégral: Iran. Biomed. J. Année: 2017

Documents relatifs à ce sujet

MEDLINE

LILACS

LIS

Recherche sur Google

Imprimer

XML